Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2010-09-07 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - annual grant of employee options 11 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, and quotation application to the ASX (Australian Securities Exchange). It includes specifics about employee options, performance rights, exercise prices, expiry dates, and trading restrictions. The document is a formal announcement related to the issuance and quotation of additional securities rather than a financial report or earnings release. It matches the description of a Capital/Financing Update, which covers company fundraising, financing activities, or capital structure changes. The document is lengthy (over 14,000 characters) and contains substantive details about the securities issued, confirming it is not merely an announcement of a report but the actual issuance notice.
2010-09-07 English
Proposed issue of options to CEO 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to the Australian Securities Exchange regarding a proposed issue of securities (performance rights) to the Chief Executive Officer. It references compliance with Listing Rule 3.10.3 and states that shareholder approval will be sought at the upcoming Annual General Meeting. The document also mentions that further details will be included in the 2010 Statutory Annual Report to be released later. The content focuses on the grant of employee options and the related approval process, not on the full annual report itself. The document length is short (2268 characters) and serves as a notification of a capital-related event (issue of securities) rather than the report or detailed financial data. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2010-09-07 English
Agreement for European Marketing of Bronchitol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 31 August 2010 announcing a strategic marketing and sales service agreement for the commercialization of Bronchitol in Europe. It discusses the company's plans, partnerships, and product details but does not contain any financial statements, regulatory filings, or detailed financial performance data. The content is promotional and informative about a business development rather than a formal financial or regulatory report. It is not an earnings release, annual report, or any other formal filing type. Given the nature of the document as a press/media release announcing a business agreement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2010-08-30 English
Preliminary Final Report 48 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'ASX Preliminary final report – 30 June 2010' and references the year ended 30 June 2010, indicating it covers a full fiscal year. It includes detailed financial statements such as income statement, statement of comprehensive income, balance sheet, and notes to the financial statements. The document also mentions it is lodged under ASX Listing Rule 4.3A, which relates to preliminary final reports. The content includes comprehensive financial data, operational commentary, audit status, and detailed financial results, consistent with a full annual report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2010
2010-08-11 English
Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX (Australian Securities Exchange) rules and regulations. It details the issuance of fully paid ordinary shares upon exercise of options under the Pharmaxis Ltd Employee Option Plan, including the number and class of securities issued, issue price, purpose, and dates related to the securities. The document is a formal announcement of new securities being issued and applying for quotation on the ASX. It does not contain financial statements, management discussion, or audit information. It is a regulatory announcement specifically about new share issues and capital changes. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is over 14,000 characters, indicating it is a full announcement rather than a brief notice or a report publication announcement.
2010-07-26 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed consolidated cash flow statements, financing activities, investing activities, and reconciliation of cash for the quarter ended 30 June 2010. It includes financial data such as receipts from customers, payments for staff costs, research and development, dividends, and cash at the end of the quarter. The document also contains compliance statements and notes related to accounting standards. The length of the document (8430 characters) and the presence of substantive financial data confirm it is a financial report rather than a brief announcement or certification. The quarterly nature and detailed financial statements align with the definition of an Interim / Quarterly Report (IR). Q4 2010
2010-07-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.